Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
| Autor: | Boran Uglesic, Andreas Schreiner, Ludger Hargarter, Robin Emsley, Abdullah Cem Sengul, Paul Bergmans, Angelina Khannanova, Pierre Cherubin, Antonino Petralia |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pediatrics
medicine.medical_specialty Neuropsychiatric Disease and Treatment Schizophrenia (object-oriented programming) Newly diagnosed paliperidone palmitate behavioral disciplines and activities 03 medical and health sciences 0302 clinical medicine long acting antipsychotic early diagnosis schizophrenia paliperidone palmitato mental disorders medicine Stage (cooking) Psychiatry Original Research Paliperidone Palmitate business.industry long-acting antipsychotic humanities 030227 psychiatry schizophrenia paliperidone palmitato Non interventional long acting antipsychotic business 030217 neurology & neurosurgery early diagnosis Neuropsychiatric disease |
| Zdroj: | Neuropsychiatric Disease and Treatment |
| ISSN: | 1178-2021 |
| DOI: | 10.2147/ndt.s142634 |
| Popis: | Robin Emsley,1 Ludger Hargarter,2 Paul Bergmans,3 Boran UglešiÄ,4 Abdullah Cem Sengül,5 Antonino Petralia,6 Angelina Khannanova,7 Pierre Cherubin,8 Andreas Schreiner2 1Stellenbosch University, Tygerberg Campus, Cape Town, South Africa; 2Janssen Cilag EMEA, Neuss, Germany, 3Janssen Cilag, Clinical Biostatistics, Breda, Netherlands; 4Department of Psychiatry, University Hospital Centre Split, Split, Croatia; 5Özel Antalya Likya Hastanesi, Antalya, Turkey; 6Department of Clinical and Experimental Medicine, School of Medicine, University of Catania, Catania, Italy; 7State Budgetary Healthcare Institution, Psychiatrc Clinical Hospital N3 named after VAGiliarovskiy, Moscow, Russia; 8Janssen Cilag EMEA, Issy-les-Moulineaux, France Background: Long-acting antipsychotic therapy may be best suited for patients in the early stage of schizophrenia, when the most can be done before disease progression associated with poor adherence occurs. We explored the patterns of use of once-monthly paliperidone palmitate (PP1M), concomitant medication use, hospitalization, and clinical outcomes of adult, newly diagnosed patients with schizophrenia receiving continuous treatment with PP1M for at least 12 months. Methods: This was an international, multicenter, exploratory, retrospective chart review of medical records of adult patients who were newly diagnosed (not more than 1 year before initiation of PP1M treatment) with schizophrenia and who had received continuous treatment with PP1M for ≥12 months in naturalistic clinical settings. Results: A total of 84 (93.3%) patients were included in the analysis. All but one patient (98.8%, n=83) had received oral antipsychotic medication at least during the last month before the first PP1M administration. Three patients (3.6%) were newly hospitalized during the 12-month documentation period. The reason for hospitalization for all three was management of episode/relapse. A total of 79.2% of patients had a ≥20% improvement and 47.2% had a ≥50% improvement in Positive and Negative Syndrome Scale total score from baseline to endpoint. Half of patients (53.3%) showed a significant improvement, as reflected by an increase in Personal and Social Performance (PSP) total score of at least 7 points from baseline to endpoint (mean [SD] 11.9 [15.0] points; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|